Aptose Biosciences Inc.
APS.TO
TSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.64M | 2.26M | 2.93M | 3.32M | 3.01M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.19M | 6.97M | 7.35M | 9.76M | 12.13M |
| Operating Income | -2.19M | -6.97M | -7.35M | -9.76M | -12.13M |
| Income Before Tax | -1.59M | -6.95M | -7.25M | -9.64M | -11.96M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.59M | -6.95M | -7.25M | -9.64M | -11.96M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.59M | -6.95M | -7.25M | -9.64M | -11.96M |
| EBIT | -2.19M | -6.97M | -7.35M | -9.76M | -12.13M |
| EBITDA | -2.18M | -6.96M | -7.34M | -9.74M | -12.11M |
| EPS Basic | -1.34 | -11.24 | -12.98 | -22.02 | -45.71 |
| Normalized Basic EPS | -0.84 | -7.02 | -8.12 | -13.76 | -28.57 |
| EPS Diluted | -1.34 | -11.24 | -12.98 | -22.02 | -45.71 |
| Normalized Diluted EPS | -0.84 | -7.02 | -8.12 | -13.76 | -28.57 |
| Average Basic Shares Outstanding | 1.19M | 618.70K | 558.50K | 437.80K | 261.50K |
| Average Diluted Shares Outstanding | 1.19M | 618.70K | 558.50K | 437.80K | 261.50K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |